essential thrombocythemia (Cancer)
Information
- Disease name
- essential thrombocythemia
- Disease ID
- DOID:2224
- Description
- "A myeloproliferative neoplasm that is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage and that results_in the overproduction of platelets." [url:http\://www.webmd.com/a-to-z-guides/thrombocythemia-essential]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00588991 | Active, not recruiting | Phase 1 | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | November 28, 2007 | March 7, 2025 |
| NCT04262141 | Active, not recruiting | Phase 2 | IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) | October 2, 2020 | October 31, 2025 |
| NCT04285086 | Active, not recruiting | Phase 3 | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | August 25, 2020 | December 30, 2025 |
| NCT03289910 | Active, not recruiting | Phase 2 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | September 24, 2018 | December 21, 2024 |
| NCT03862157 | Active, not recruiting | Phase 1/Phase 2 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | February 27, 2019 | January 31, 2025 |
| NCT00112593 | Completed | N/A | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | November 1999 | |
| NCT00227591 | Completed | Phase 2 | Lenalidomide and Prednisone in Treating Patients With Myelofibrosis | December 2005 | December 2010 |
| NCT00357305 | Completed | Phase 1 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | May 2006 | |
| NCT00381550 | Completed | Phase 2 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | August 2006 | March 2011 |
| NCT00397813 | Completed | Phase 2 | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | January 2006 | March 2018 |
| NCT00445744 | Completed | N/A | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | December 2006 | June 2013 |
| NCT00489203 | Completed | Phase 2 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | April 2007 | |
| NCT00665067 | Completed | Correlative Biomarker Study in Patients With Myeloproliferative Disorders | April 2007 | July 20, 2018 | |
| NCT00666289 | Completed | Familial Myeloproliferative Disorders | March 2008 | June 20, 2015 | |
| NCT00666549 | Completed | Research Tissue Bank | September 2007 | March 27, 2017 | |
| NCT00715247 | Completed | Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes | July 2006 | December 2018 | |
| NCT00025415 | Completed | Phase 1 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | August 2001 | |
| NCT00745550 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis | August 2008 | January 2012 |
| NCT00890747 | Completed | Phase 1 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | August 2009 | |
| NCT01053494 | Completed | N/A | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | April 2010 | February 2012 |
| NCT01192347 | Completed | French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia | September 13, 2010 | December 21, 2012 | |
| NCT01199562 | Completed | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | December 2010 | December 2013 | |
| NCT01243073 | Completed | Phase 2 | Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera | December 2010 | April 2015 |
| NCT01384513 | Completed | Phase 2 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | August 4, 2011 | November 16, 2022 |
| NCT01387763 | Completed | Phase 3 | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms | January 2012 | June 2020 |
| NCT01520220 | Completed | Phase 1 | Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms | June 11, 2012 | February 24, 2017 |
| NCT01588015 | Completed | Phase 1 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | October 29, 2012 | February 2, 2024 |
| NCT01787552 | Completed | Phase 1/Phase 2 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | May 8, 2013 | April 10, 2018 |
| NCT01831635 | Completed | Myeloproliferative Neoplasms: an In-depth Case-control Study | April 2013 | June 2015 | |
| NCT01970930 | Completed | Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients | August 2012 | June 2, 2016 | |
| NCT02076815 | Completed | Phase 3 | Anagrelide Retard in Essential Thrombocythemia | February 2014 | April 2015 |
| NCT02124746 | Completed | Phase 2 | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia | April 30, 2014 | December 6, 2018 |
| NCT02129101 | Completed | Phase 1 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | May 2014 | October 25, 2019 |
| NCT02311569 | Completed | Phase 2 | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | April 2015 | December 2016 |
| NCT02407080 | Completed | Phase 1 | Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia | April 2015 | December 19, 2018 |
| NCT02556931 | Completed | Phase 2 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | December 2015 | April 2021 |
| NCT00718159 | Completed | Phase 1 | Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia | August 2008 | December 2011 |
| NCT00039416 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Myelofibrosis | April 2002 | |
| NCT00047190 | Completed | Phase 2 | Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia | August 2002 | |
| NCT00052520 | Completed | Phase 1/Phase 2 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | September 2002 | June 2013 |
| NCT00089011 | Completed | Phase 2 | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer | April 2004 | July 2018 |
| NCT02823184 | Completed | Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms | April 27, 2017 | April 27, 2019 | |
| NCT02893410 | Completed | Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients | December 2014 | December 2015 | |
| NCT03232177 | Completed | Phase 4 | Anagre Cap. in Patients With High-Risk Essential Thrombocythemia | June 5, 2017 | December 5, 2020 |
| NCT03566446 | Completed | Phase 1 | CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms | June 20, 2018 | April 30, 2021 |
| NCT03745378 | Completed | Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) | May 15, 2018 | September 30, 2018 | |
| NCT03907436 | Completed | N/A | The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase | October 1, 2018 | October 1, 2019 |
| NCT04051307 | Completed | Phase 1/Phase 2 | Dual Vaccine Trial in Myeloproliferative Neoplasms | July 10, 2019 | July 10, 2022 |
| NCT04254978 | Completed | Phase 2 | Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) | September 8, 2020 | March 23, 2023 |
| NCT06371573 | Completed | Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms | April 20, 2017 | March 20, 2024 | |
| NCT06456346 | Not yet recruiting | Phase 3 | Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | August 5, 2024 | May 14, 2029 |
| NCT06079879 | Recruiting | Phase 3 | A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | December 31, 2023 | August 18, 2028 |
| NCT06150157 | Recruiting | Phase 1 | A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | December 20, 2023 | November 19, 2026 |
| NCT06063486 | Recruiting | Phase 2 | Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | March 1, 2024 | March 1, 2027 |
| NCT04644211 | Recruiting | Phase 2 | Ruxolitinib in Thrombocythemia and Polycythemia Vera | March 21, 2022 | December 2024 |
| NCT04942080 | Recruiting | N/A | Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) | October 28, 2021 | April 28, 2026 |
| NCT05025488 | Recruiting | Phase 1 | Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | April 4, 2023 | March 2026 |
| NCT05031897 | Recruiting | Phase 2 | Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | October 25, 2021 | October 1, 2024 |
| NCT05123365 | Recruiting | Phase 1/Phase 2 | An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms | January 3, 2022 | November 15, 2026 |
| NCT05198960 | Recruiting | Phase 3 | AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms | July 13, 2022 | July 13, 2027 |
| NCT02760238 | Recruiting | Myeloproliferative Neoplasms (MPNs) Patient Registry | April 2016 | October 2025 | |
| NCT05482971 | Recruiting | Phase 2 | A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET | September 29, 2022 | December 31, 2026 |
| NCT05882773 | Recruiting | Asian Myeloproliferative Neoplasm (MPN) Registry | May 2023 | December 2026 | |
| NCT02897297 | Recruiting | Myeloproliferative Neoplastic Diseases Observatory From Brest | September 2015 | September 2025 | |
| NCT03869476 | Recruiting | N/A | Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. | July 30, 2019 | January 30, 2024 |
| NCT03878199 | Recruiting | Phase 1/Phase 2 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | February 20, 2019 | December 31, 2024 |
| NCT06361641 | Recruiting | N/A | Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes | May 29, 2024 | October 19, 2027 |
| NCT06378437 | Recruiting | Phase 1 | A Study of GLB-001 in Patients With Myeloid Malignancies | May 24, 2024 | December 31, 2027 |
| NCT04282187 | Recruiting | Phase 2 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | March 24, 2020 | November 11, 2026 |
| NCT01014546 | Terminated | Phase 1 | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | April 2010 | February 2015 |
| NCT03972943 | Terminated | Early Phase 1 | CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia | May 15, 2019 | July 28, 2023 |
| NCT01998828 | Terminated | Phase 2 | Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia | February 19, 2014 | May 7, 2015 |
| NCT03121599 | Terminated | N/A | 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms | June 11, 2017 | October 16, 2018 |
| NCT02962388 | Terminated | Phase 2/Phase 3 | The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line | January 3, 2017 | June 28, 2021 |
| NCT00866762 | Unknown status | Phase 2 | A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia | February 2009 | December 2012 |
| NCT03116542 | Unknown status | N/A | 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia | May 7, 2017 | August 2021 |
| NCT02611973 | Unknown status | Phase 3 | Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia | March 10, 2016 | November 2022 |
| NCT00668421 | Unknown status | Phase 1/Phase 2 | CEP-701 (Lestaurtinib) in Myelofibrosis | April 2008 | January 2015 |
| NCT02663648 | Withdrawn | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders | June 2016 | June 2020 |
- Disase is a (Disease Ontology)
- DOID:2226
- Cross Reference ID (Disease Ontology)
- GARD:6594
- Cross Reference ID (Disease Ontology)
- ICD10CM:D47.3
- Cross Reference ID (Disease Ontology)
- ICD9CM:238.71
- Cross Reference ID (Disease Ontology)
- ICDO:9962/3
- Cross Reference ID (Disease Ontology)
- MESH:D013920
- Cross Reference ID (Disease Ontology)
- MIM:187950
- Cross Reference ID (Disease Ontology)
- MIM:601977
- Cross Reference ID (Disease Ontology)
- MIM:614521
- Cross Reference ID (Disease Ontology)
- NCI:C3407
- Cross Reference ID (Disease Ontology)
- ORDO:3318
- Cross Reference ID (Disease Ontology)
- ORDO:71493
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:234499005
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0040028
- Exact Synonym (Disease Ontology)
- Essential thrombocythaemia
- Exact Synonym (Disease Ontology)
- familial thrombocytosis
- Exact Synonym (Disease Ontology)
- hemorrhagic thrombocythemia
- Exact Synonym (Disease Ontology)
- hereditary thrombocythemia
- Exact Synonym (Disease Ontology)
- primary Thrombocytosis
- OrphaNumber from OrphaNet (Orphanet)
- 3318